Sesquiterpenoids from the hydrothermal vent sediment derived fungus Penicillium sp. JWM79-5-1 with antithrombotic and pro-angiogenic activities
Wenjuan Ding , Xiaobin Li , Xiyue Wang , Shuqing Yu , Xunuo Li , FangFang Wang , Danmei Tian , Bin Wu , Jinshan Tang
Marine Life Science & Technology ›› : 1 -14.
Sesquiterpenoids from the hydrothermal vent sediment derived fungus Penicillium sp. JWM79-5-1 with antithrombotic and pro-angiogenic activities
Seven previously unreported sesquiterpenes including three rare 5/5/6-fused tricyclic gymnomitrane-type sesquiterpenes (1–3), an ent-longipinane-type sesquiterpene (4), a cuparane-type sesquiterpene (5), and two chamigrane-type sesquiterpenes (6 and 7), along with a known chamigrane-type sesquiterpene xylariterpenoid C (8) were isolated from the hydrothermal vent sediment derived fungus Penicillium sp. JWM79-5–1. Their structures were identified on the basis of 1D and 2D NMR, in conjunction with Mosher’s method, X-ray crystallography, and electronic circular dichroism (ECD). The antithrombotic activity of compounds 1–6 and 8 was evaluated in arachidonic acid (AA)-induced zebrafish thrombosis model in vivo. The results revealed compound 1 with potent antithrombotic activity in a concentration-dependent manner. Further, the pro-angiogenic activities of compounds 1–6 and 8 were evaluated in a transgenic zebrafish model that expresses vegfr2, the receptor for the angiogenic factor VEGF, tagged with the green fluorescence protein (vegfr2-GFP) through detecting the length of both intersegmental vessels (ISVs) and subintestinal veins (SIVs). The results revealed that compound 1 exhibited a potent antithrombotic activity while 3 revealed a potent pro-angiogenic activity. These findings strongly support drug development of these compounds in cardiovascular disease treatment.
Marine-derived fungus / Secondary metabolites / Sesquiterpenes / Antithrombotic activity / Pro-angiogenic activity
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
Eisai Co Ltd (2011) Eisai announces canadian approval of its anticancer agent HalavenTM. https://www.eisai.com/news/news201179.html. Accessed 15 Dec 2011 |
| [14] |
European Medicines Agency (2023) Halaven. https://www.ema.europa.eu/en/medicines/human/EPAR/halaven. Accessed 23 Oct 2011 |
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
Ocean University of China
/
| 〈 |
|
〉 |